Physician profile
Frank Parasmo
NPI 1710094008
$8,292.58
in general payments reported to CMS, 2019-2025
33 companies · $23.48 in 2025
The $23.48 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,653 · 2020: $1,827 · 2021: $1,533 · 2022: $1,609 · 2023: $647 · 2025: $23.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,533.28 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,122.61 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $825.99 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $716.29 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Pfizer INC. | $665.94 | 2019-2023 | |
| Abbvie INC. | $456.31 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $454.41 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $393.68 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $375.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $324.19 | 2019-2023 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $225.75 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $220.04 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $138.83 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.00 | 2019-2022 | |
| Exact Sciences Corporation | $71.44 | 2023 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $67.04 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.34 | 2019 | |
| Hikma Pharmaceuticals USA | $62.22 | 2019-2021 | |
| Abbott Laboratories | $54.87 | 2019-2021 | |
| Sanofi Pasteur INC. | $53.63 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $46.23 | 2019 | |
| Genentech USA, INC. | $40.50 | 2019-2022 | |
| Alfasigma USA, INC. | $40.22 | 2021 | |
| Astellas Pharma US INC | $34.87 | 2019 | |
| Depuy Synthes Sales INC. | $34.23 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $31.81 | 2019 | |
| Bioxcel Therapeutics, INC. | $27.84 | 2023 | Igalmi |
| Intuity Medical INC | $26.28 | 2022 | |
| Daiichi Sankyo INC. | $20.47 | 2020 | |
| Radius Health, INC. | $17.35 | 2019 | |
| Eyevance Pharmaceuticals LLC | $16.70 | 2021 | |
| Nabriva Therapeutics, Plc | $11.50 | 2021 | |
| Insulet Corporation | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Parasmo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.